Nanoparticles boost glioblastoma survival 50% in mice
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Oregon State University researchers developed mannose-coated lipid nanoparticles that exploit the GLUT1 glucose transporter to cross the blood-brain barrier, increasing median survival by 50% in mice with glioblastoma
- The nanoparticles carried mRNA directing cells to produce PTEN, a tumor-suppressor protein that is often missing or inactive in glioblastoma cells, reinstating growth control in tumors
- Taratula's team improved nanoparticle surface coverage sixfold by chemically attaching mannose to cholesterol, enabling the particles to outcompete blood glucose for GLUT1 access into the brain
- Glioblastoma cells express GLUT1 at three times the level of normal brain tissue, causing the sugar-coated particles to preferentially accumulate inside tumors after crossing the barrier
- Across repeated dosing in the mouse study, the researchers observed tumor shrinkage with no measurable organ toxicity in other tissues
- Glioblastoma affects roughly 3.19 per 100,000 people in the U.S., has a median diagnosis age of 64, and kills more than 95% of patients within five years
- The study, published in the Journal of Controlled Release, was supported by the National Cancer Institute, the NICHD, and the National Research Foundation of Korea
Why it matters: Glioblastoma kills more than 95% of patients within five years, and no current therapy reliably crosses the blood-brain barrier without collateral damage. By hijacking the brain's own glucose-transport machinery to deliver tumor-suppressor mRNA, the Oregon State approach offers a dual-targeting strategy that hits tumors preferentially while sparing healthy organs — clearing a promising first mouse-model hurdle for an indication that has stumped drug developers for decades.
